Effect of Teduglutide on Gastric Emptying in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
NPS Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01209351
First received: September 20, 2010
Last updated: January 4, 2012
Last verified: January 2012
  Purpose

The primary objective of this study is to assess the effects of 10 consecutive, daily, subcutaneous doses of 4 mg of teduglutide as compared with placebo on gastric emptying as assessed by acetaminophen absorption kinetics in healthy subjects.


Condition Intervention Phase
Healthy Volunteers
Drug: Placebo
Drug: teduglutide
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dosing, Parallel Group Study to Assess the Effects of Teduglutide (ALX-0600) on Gastric Emptying in Healthy Subjects

Resource links provided by NLM:


Further study details as provided by NPS Pharmaceuticals:

Primary Outcome Measures:
  • PK log-transformed parameters AUC and CMax [ Time Frame: Day 10 ] [ Designated as safety issue: No ]
    The primary objective of this study is to assess the effects of 10 consecutive, daily, subcutaneous doses of 4 mg of teduglutide as compared with placebo on gastric emptying as assessed by acetaminophen absorption kinetics in healthy subjects.


Secondary Outcome Measures:
  • AUC for each GI blood markers [ Time Frame: day 10 ] [ Designated as safety issue: No ]
    The secondary objectives of this study are to assess the effects of subcutaneous dosing of 4 mg of teduglutide administered in single daily doses on the pharmacokinetics of teduglutide on the AUC 3 hours post dose on insulin, glucose, and glucagon.

  • CMax [ Time Frame: Day 10 ] [ Designated as safety issue: No ]
    The secondary objectives of this study are to assess the effects of subcutaneous dosing of 4 mg of teduglutide administered in single daily doses on the pharmacokinetics of teduglutide on the cMax 3 hours post dose on insulin, glucose, and glucagon.


Enrollment: 36
Study Start Date: October 2010
Study Completion Date: January 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo
Drug: Placebo
placebo
Experimental: teduglutide Drug: teduglutide
teduglutide 4 mg

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Informed of the nature of the study and have agreed to and are able to read, review, understand, and sign the informed consent document prior to any screening assessments being completed.
  2. Completed the screening process within 30 days prior to check in
  3. Adult males or females age 18 to 45 years in good health as determined by medical history, physical examination, ECG, and laboratory tests
  4. Women who are: (1) post-menopausal; (2) surgically sterilized, OR (3) of childbearing potential with a negative pregnancy test at screening and check-in and who consent to use an acceptable method of contraception for the duration of the study and for four weeks following last dose of study drug.

Exclusion Criteria:

  1. Allergy or sensitivity to acetaminophen
  2. History of structural abnormality or pathology of the GI tract or diseases/conditions which affect GI motility including the following:

Gastric, small bowel or colonic resection, Colon cancer or any GI Tract cancer Inflammatory bowel disease, Irritable bowel disease, Diabetes Mellitus, Gallstones or cholecystectomy, Appendectomy, hernia repair, benign polypectomy are not excluded, History of Gilbert's Syndrome 3 History of hepatitis or pancreatitis 4 Evidence of any abnormal hepatobiliary laboratory parameters (> ULN for serum ALT; AST; ALP; GGT; and/or total, direct or indirect bilirubin) 5 Serum amylase or lipase above the upper limit of normal 6 Body mass index (BMI) > 30 kg/m2 7 Intention to use medication that potentially affects GI tract motility 8 History of a viral or bacterial infection, allergy, other inflammatory process or surgery within 3 weeks of the check-in day.

9 Clinical evidence or history (including that from medical and medication history, physical examination, laboratory, ECG and any other available test results such as those from medical imaging studies) of significant cardiovascular, respiratory, renal, gastrointestinal, hematologic (eg, anemia), neurologic, psychiatric conditions or of any disease that may interfere with the objectives of the study or with the subject successfully completing the study 10 Presently taking prescription or over the counter medication including products containing acetaminophen, vitamins, herbs or dietary supplements, which cannot be discontinued. Prohibited medications must be discontinued at least 7 days prior to check-in and all other medications and supplements must be stopped at least 72 hours prior to check-in.

11 Current or recent history (within 12 months) of drug or alcohol abuse 12 Positive drug or alcohol screen 13 Current or recent history (within 3 months) of use of tobacco products 14 Positive urine cotinine screen 15 Abnormalities in clinical chemistry, hematology, urinalysis or in any other laboratory variables 16 Positive results in any of the virology tests of acute or chronic infectious human immunodeficiency virus (HIV) and hepatitis virus infections 17 Pregnant or lactating females; positive beta human chorionic gonadotropin (b-hCG) pregnancy test in females only 18 Special dietary requirements which would preclude a subject's acceptance of a high fat or high caloric, standardized meal 19 Blood donation within 4 weeks of the check-in day 20 Participation in another clinical trial with an investigational drug or device within the last month (if single dose) and at least 3 months (if multiple dose) or within 10 times the half-life of the respective investigational drug, whatever is longer, before the screening evaluation. For biologics the minimum period is at least 6 months or the time of duration of the pharmacodynamic effect or 10 times the half-life of the respective drug, whatever is longer, before the screening evaluation.

21 Lack of ability or willingness to give informed consent

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01209351

Locations
United States, Texas
Cetero Clinical Research
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
NPS Pharmaceuticals
Investigators
Principal Investigator: Jolene Berg, MD Cetero Research, San Antonio
  More Information

No publications provided by NPS Pharmaceuticals

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: NPS Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01209351     History of Changes
Other Study ID Numbers: C10-003
Study First Received: September 20, 2010
Last Updated: January 4, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by NPS Pharmaceuticals:
Pharmacokinetics
Pharmacodynamics
teduglutide

ClinicalTrials.gov processed this record on September 18, 2014